PLX3397
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Glioblastoma
Conditions
Recurrent Glioblastoma
Trial Timeline
Dec 3, 2011 → Nov 5, 2013
NCT ID
NCT01349036About PLX3397
PLX3397 is a phase 2 stage product being developed by Daiichi Sankyo for Recurrent Glioblastoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01349036. Target conditions include Recurrent Glioblastoma.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent Glioblastoma were approved
Approved (4) Terminated (0) Active (16)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02975700 | Pre-clinical | Completed |
| NCT01499043 | Phase 2 | Terminated |
| NCT01349036 | Phase 2 | Terminated |
| NCT01217229 | Phase 2 | Completed |
| NCT01004861 | Phase 1 | Completed |
Competing Products
20 competing products in Recurrent Glioblastoma